Real-World Evidence as a Driver of Precision Oncology and Personalized Therapeutic Sequencing in Later-Line Metastatic Colorectal Cancer
- 1Medical Oncology Unit, Santa Rosa Hospital, Azienda Sanitaria Locale Viterbo, 01100 Viterbo, Italy
Abstract
Background: The therapeutic landscape of refractory metastatic colorectal cancer (mCRC) has expanded with antiangiogenic agents, cytotoxic therapies, immunotherapy, and biomarker-driven treatments. Randomized clinical trials (RCTs) establish efficacy and safety, while real-world evidence (RWE) can complement them by addressing generalizability, treatment delivery, safety, and outcomes in populations underrepresented in prospective studies. This narrative review examines the contribution and limitations of RWE in precision oncology and later-line therapeutic sequencing in mCRC. Methods: We reviewed evidence from randomized trials, observational studies, real-world registries, translational research, and contemporary international guidance, focusing on later-line antiangiogenic strategies, trifluridine/tipiracil-based treatment, fruquintinib, anti-EGFR rechallenge, immunotherapy in MSI-H/dMMR disease, and targeted therapies for actionable molecular alterations. Particular attention was given to RWE methodology and interpretation. Results: RWE complements randomized evidence by characterizing effectiveness and toxicity in heterogeneous populations, treatment delivery and dose modification, and implementation of biomarker-guided strategies in routine practice. Observational studies may also inform therapeutic sequencing and identify prognostic or pharmacodynamic correlates, although causal interpretation is limited by selection bias, treatment attrition, time-dependent and residual confounding. Longitudinal circulating tumor DNA (ctDNA) assessment is particularly relevant to molecular reassessment and anti-EGFR rechallenge, while broader ctDNA-guided adaptive treatment strategies remain investigational. Conclusions: Later-line mCRC management increasingly integrates molecular profiling, treatment history, patient fitness, toxicity, and therapeutic sequencing. High-quality RWE provides complementary evidence on how these strategies perform and are implemented in routine practice but should be interpreted according to study design and susceptibility to bias. Integration of rigorous RWE with randomized and prospective molecular evidence may help bridge the gap between trial efficacy and real-world effectiveness and support individualized later-line care.
Related
- Integrated Multi-Omic Analysis of Paired Primary and Peritoneal Metastatic Tumors Reveals GPAA1 as a Therapeutic Target in Colorectal Cancer
- Combined casein kinase II and MAPK signalling inhibition as a therapeutic strategy for metastatic colorectal cancer
- Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards
- Association between primary-site surgery and overall survival in non-metastatic and metastatic colorectal cancer: a population-based study using the Surveillance, Epidemiology, and End Results database
- HER3 mediates metabolic reprogramming in metastatic colorectal and pancreatic cancer
BibTeX
@article{signorelli2026realworld,
title = {{Real-World Evidence as a Driver of Precision Oncology and Personalized Therapeutic Sequencing in Later-Line Metastatic Colorectal Cancer}},
author = {Carlo Signorelli},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18193174},
url = {https://www.mdpi.com/2072-6694/18/19/3174},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Real-World Evidence as a Driver of Precision Oncology and Personalized Therapeutic Sequencing in Later-Line Metastatic Colorectal Cancer
AU - Carlo Signorelli
PY - 2026
DA - 2026/10/01
JO - Cancers
DO - 10.3390/cancers18193174
UR - https://www.mdpi.com/2072-6694/18/19/3174
AB - Background: The therapeutic landscape of refractory metastatic colorectal cancer (mCRC) has expanded with antiangiogenic agents, cytotoxic therapies, immunotherapy, and biomarker-driven treatments. Randomized clinical trials (RCTs) establish efficacy and safety, while real-world evidence (RWE) can complement them by addressing generalizability, treatment delivery, safety, and outcomes in populations underrepresented in prospective studies. This narrative review examines the contribution and limitations of RWE in precision oncology and later-line therapeutic sequencing in mCRC. Methods: We reviewed evidence from randomized trials, observational studies, real-world registries, translational research, and contemporary international guidance, focusing on later-line antiangiogenic strategies, trifluridine/tipiracil-based treatment, fruquintinib, anti-EGFR rechallenge, immunotherapy in MSI-H/dMMR disease, and targeted therapies for actionable molecular alterations. Particular attention was given to RWE methodology and interpretation. Results: RWE complements randomized evidence by characterizing effectiveness and toxicity in heterogeneous populations, treatment delivery and dose modification, and implementation of biomarker-guided strategies in routine practice. Observational studies may also inform therapeutic sequencing and identify prognostic or pharmacodynamic correlates, although causal interpretation is limited by selection bias, treatment attrition, time-dependent and residual confounding. Longitudinal circulating tumor DNA (ctDNA) assessment is particularly relevant to molecular reassessment and anti-EGFR rechallenge, while broader ctDNA-guided adaptive treatment strategies remain investigational. Conclusions: Later-line mCRC management increasingly integrates molecular profiling, treatment history, patient fitness, toxicity, and therapeutic sequencing. High-quality RWE provides complementary evidence on how these strategies perform and are implemented in routine practice but should be interpreted according to study design and susceptibility to bias. Integration of rigorous RWE with randomized and prospective molecular evidence may help bridge the gap between trial efficacy and real-world effectiveness and support individualized later-line care.
SN - 2072-6694
ER -